Clinical Trial Update: Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) [Phase 2]

View source ↗

Summary

Phase 2 trial update on afatinib plus pembrolizumab for head and neck squamous cell carcinoma (ALPHA Study) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Head and Neck Neoplasms | Phase 2 | Status: COMPLETED